Table 2 Comparison of clinical features and prognosis between hepatotropic viral insult and non-virus insult groups
|  | Total (n = 203) | HVI (n = 82) | NVI (n = 121) | P value |
|---|---|---|---|---|
Age,years | 47.7 ± 11.4 | 49.3 ± 9.6 | 46.6 ± 12.4 | 0.087 |
Male,no(%) | 161(79.3) | 64(73.1) | 97(80.2) | 0.715 |
ACLF Type, no (%) A B C | 59 (29.1) 75 (36.9) 69 (34.0) | 24 (29.3) 34 (41.5) 24 (29.3) | 35 (28.9) 41 (33.9) 45 (37.2) | 0.435 |
Exacerbation time frame, days, median (IQR) | 14 (23) | 20 (20) | 10 (14) | 0.003 |
Laboratory data | ||||
 ALT, IU/L median (IQR) | 185.0 (470.5) | 151.7 (535.7) | 219 (472.5) | 0.927 |
 AST, IU/L median (IQR) | 203.3 (374.4) | 184.5 (460.4) | 207.0 (394.1) | 0.785 |
 Albumin, g/L mean(SD) | 29.9 ± 5.1 | 31.5 ± 4.8 | 28.9 ± 5.1 | 0.000 |
 GGT,IU/L median (IQR) | 85.0 (83.8) | 92.0 (101) | 82.0 (77.5) | 0.091 |
 TB, umol/L median (IQR) | 263.3 (224.4) | 285.8 (215.4) | 252.4 (216.6) | 0.216 |
 Na, mmol/L median (IQR) | 135.1 (5.5) | 134.6 (5.5) | 135.2 (5.8) | 0.788 |
 Creatinine, umol/L median (IQR) | 72.0 (37.0) | 68 (36.5) | 76(38.5) | 0.195 |
 WBC, 109/L median (IQR) | 6.2 (4.5) | 5.8 (8.6) | 6.8 (4.2) | 0.227 |
 NEUT, % median (IQR) | 72.0 (14.6) | 71.4 (15.3) | 72.0 (15.0) | 0.880 |
 Platelet, 109/L median (IQR) | 79 (70) | 79 (117) | 80 (61) | 0.845 |
 PTA,% median (IQR) | 33.8 (13.6) | 33.6(14.3) | 34 (13.2) | 0.896 |
 INR median (IQR) | 2.1 (0.8) | 2.1 (0.9) | 2.1 (0.8) | 0.707 |
Severity score | ||||
 CTP median (IQR) | 11.0( 2) | 11.0 (2) | 11.0 (2) | 0.134 |
 MELD mean (SD) | 23.6 ± 5.4 | 23.7 ± 6.1 | 23.5 ± 4.9 | 0.830 |
 CLIF-SOFA median (IQR) | 7 (1) | 7 (2) | 7 (1) | 0.660 |
 Lactate free AARC median (IQR) | 7 (1) | 9 (2) | 8 (3) | 0.738 |
 CLIF-ACLF median (IQR) | 39.2 (12.7) | 41.3 (11.7) | 38.3 (12.8) | 0.188 |
Cumulative mortality | ||||
 28 day, no (%) | 37 (18.2) | 19 (20.9) | 18 (13.7) | 0.125 |
 90 day, no (%) | 65 (32.0) | 33 (36.3) | 32 (24.4) | 0.020 |
 1 year, no (%) | 72 (35.5) | 36 (39.5) | 36 (27.5) | 0.014 |